相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Michael O. Meyers et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
Gunter von Minckwitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
V. Semiglazov et al.
EJSO (2011)
LOCOREGIONAL RECURRENCE OF BREAST CANCER IN PATIENTS TREATED WITH BREAST CONSERVATION SURGERY AND RADIOTHERAPY FOLLOWING NEOADJUVANT CHEMOTHERAPY
Sun Young Min et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
M. E. Straver et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2010)
Locoregional Treatment of Primary Breast Cancer Consensus Recommendations From an International Expert Panel
Manfred Kaufmann et al.
CANCER (2010)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Seung Il Kim et al.
ONCOLOGY (2010)
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
Marco Colleoni et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Breast Conservation Therapy for Patients With Locally Advanced Breast Cancer
Mohamed A. Alm El-Din et al.
SEMINARS IN RADIATION ONCOLOGY (2009)
Prognostic value of initial clinical disease stage after achieving pathological complete response
Shaheenah Dawood et al.
ONCOLOGIST (2008)
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
Aman U. Buzdar et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
Suleiman Massarweh et al.
CANCER RESEARCH (2006)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
MC Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
LA Carey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience
AM Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer:: the role of clinical response
JY Pierga et al.
EUROPEAN JOURNAL OF CANCER (2003)
Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902
JA van der Hage et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)